With an increasingly promising roster of approved cell therapies still burdened by complex manufacturing, multiple companies ...
Pfizer's Dave Denton is heading back to his consumer goods roots after a four-year tenure at the New York pharma. (iStock/Getty Images Plus) Pfizer’s chief financial officer Dave Denton will soon wave ...
A deviation gets flagged on a 2,000-liter batch. The product sits on hold until someone can explain what happened and whether ...
The FTC is requiring Aurobindo to divest four drugs to complete its $250 million acquisition of Pennsylvania generics specialist Lannet. (Getty Images/LD) Before Indian drugmaker Aurobindo can ...
Four years after Spero Therapeutics received a complete response letter from the FDA, rejecting its oral treatment for ...
After disclosing a security breach last week concerning “a limited number of internal IT systems,” details on the cyber ...
What’s been Novo Nordisk's secret weapon to turn the tables on Eli Lilly and win the current market battle over their oral GLP-1 obesity drugs? Name recognition. | Name recognition and "familiarity" ...
With good-but-not-great updated data on its approved oncology combo of avutometinib plus defactinib (A+D) in first-line ...
With pharma and life sciences deal values surpassing $65 billion in Q1, marking the strongest quarter in the industry since ...
In another Novo Nordisk manufacturing update, the company announced locally that it will invest 200 million yuan ($29 million ...
TV spot for Exdensur, stepping up promotion of an asthma drug that th | GSK has launched the first direct-to-consumer TV spot ...
While describing the new import approval as a “tremendous step toward making prescription drugs affordable for all Coloradans ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results